Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Via News Knowledge File

BlackRock, Inc.

organization80% conf.·synced Oct 15, 2026

Investment management firm

60
sourced metrics
707
relationships
20
stated objectives
1
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week Low
922.90USD
Oct 14, 2026reference only
Market Cap
166358183896USD
Oct 14, 2026reference only
Stock Return Ytd
-1.0%
Oct 14, 2026reference only
Stock Price
1073.79USD
Oct 14, 2026reference only
Price 52 Week High
1202.59USD
Oct 14, 2026reference only
Total Assets
175875000000.0USD
Jun 30, 2026reference only
Eps
12.19USD_per_share
Jun 30, 2026reference only
Stockholders Equity
57613000000.0USD
Jun 30, 2026reference only
Cash
10492000000.0USD
Jun 30, 2026reference only
Shares Outstanding
154996807.0shares
Jun 30, 2026reference only
Revenue
7084000000.0USD
Jun 30, 2026reference only
Total Liabilities
111335000000.0USD
Jun 30, 2026reference only
Net Income
1914000000.0USD
Jun 30, 2026reference only
Operating Income
2461000000.0USD
Jun 30, 2026reference only
Capex
106000000.0USD
Mar 31, 2026reference only
Operating Cash Flow
-980000000.0USD
Mar 31, 2026reference only

Stated objectives

Maintain adjusted operating margin of 45% or greater

source
target: 45% or greater stated

Grow private markets to insurance, private markets to wealth, digital assets, and active ETFs each to $500 million in annual revenue

source
target: $500 million per initiative by 2030-01-01 00:00:00stated

Target $400 billion in gross private markets fundraising through 2030

source
target: 400 billion USD by 2030-01-01 00:00:00stated

Target mid-single-digit percentage increase in G&A and broadly flat headcount in 2026 after annualizing HPS and Preqin impacts

source
target: mid-single-digit % G&A increase; flat headcount by 2026-12-31 00:00:00stated

Deploy capital for roughly 20 late-stage insurance client conversations to build diversified portfolios across public and private markets, with deployments expected to pull through second half of 2026

source
target: 20 late-stage insurance conversations by 2026-12-31 00:00:00stated

Target $1.8 billion in share repurchases during 2026

source
target: 1.8 billion USD by 2026-12-31 00:00:00stated

Recommends Bitcoin allocation of 1-2% in multi-asset portfolios

source
target: 1-2% stated

See retail as a vast untapped pool of capital for private markets

source
stated

BlackRock requires $3 billion in XRP ETF demand threshold before filing XRP ETF application

source
target: 3000000000 stated

Generate $500 million in annual revenue from crypto business

source
target: 500000000 by 2031-01-01 00:00:00stated

Relationship graph · 707 connections

subsidiary of
204
Developed by
138
Invested in
71
Employs
62
managed by
42
Covered by
30
Owns
29
headquartered in
27
board member of
Hans Vestberg
Partners with
AcornsSecuritize

Via News coverage

Heimstaden AB AGM Signals Governance Shift as European Real Estate Gains 6% in February
March 1, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com